keyword
MENU ▼
Read by QxMD icon Read
search

Cataract dme

keyword
https://www.readbyqxmd.com/read/29776671/guidelines-on-diabetic-eye-care-the-international-council-of-ophthalmology-recommendations-for-screening-follow-up-referral-and-treatment-based-on-resource-settings
#1
REVIEW
Tien Y Wong, Jennifer Sun, Ryo Kawasaki, Paisan Ruamviboonsuk, Neeru Gupta, Van Charles Lansingh, Mauricio Maia, Wanjiku Mathenge, Sunil Moreker, Maji M K Muqit, Serge Resnikoff, Juan Verdaguer, Peiquan Zhao, Frederick Ferris, Lloyd P Aiello, Hugh R Taylor
Diabetes mellitus (DM) is a global epidemic and affects populations in both developing and developed countries, with differing health care and resource levels. Diabetic retinopathy (DR) is a major complication of DM and a leading cause of vision loss in working middle-aged adults. Vision loss from DR can be prevented with broad-level public health strategies, but these need to be tailored to a country's and population's resource setting. Designing DR screening programs, with appropriate and timely referral to facilities with trained eye care professionals, and using cost-effective treatment for vision-threatening levels of DR can prevent vision loss...
May 15, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29697589/dexamethasone-implant-for-diabetic-macular-edema-in-naive-compared-with-refractory-eyes-the-international-retina-group-real-life-24-month-multicenter-study-the-irgrel-dex-study
#2
Matias Iglicki, Catharina Busch, Dinah Zur, Mali Okada, Miriana Mariussi, Jay Kumar Chhablani, Zafer Cebeci, Samantha Fraser-Bell, Voraporn Chaikitmongkol, Aude Couturier, Ermete Giancipoli, Marco Lupidi, Patricio J Rodríguez-Valdés, Matus Rehak, Adrian Tien-Chin Fung, Michaella Goldstein, Anat Loewenstein
PURPOSE: To investigate efficacy and safety of repeated dexamethasone (DEX) implants over 24 months, in diabetic macular edema (DME) eyes that were treatment naive compared with eyes refractory to anti-vascular endothelial growth factor treatment, in a real-life environment. METHODS: This multicenter international retrospective study assessed best-corrected visual acuity and central subfield thickness (CST) of naive and refractory eyes to anti-vascular endothelial growth factor injections treated with dexamethasone implants...
April 24, 2018: Retina
https://www.readbyqxmd.com/read/29649995/the-prevalence-and-systemic-risk-factors-of-diabetic-macular-edema-a-cross-sectional-study-from-turkey
#3
Durgul Acan, Mehmet Calan, Duygu Er, Tugba Arkan, Nilufer Kocak, Firat Bayraktar, Suleyman Kaynak
BACKGROUND: The aim of this study was to evaluate the prevalence of diabetic macular edema (DME) utilizing optical coherence tomography (OCT), and to clarify the effects of the systemic findings and risk factors on the development of DME. METHODS: This cross-sectional study was conducted in the departments of ophthalmology and endocrinology at the Dokuz Eylul University School of Medicine in Izmir, Turkey. The demographics, type and duration of diabetes mellitus, treatment modality, smoking and alcohol consumption habits, as well as the systemic blood pressure, renal functional tests, hemoglobulin A1c level, serum lipid profile, and 24-h urine albumin level were noted and statistically analyzed...
April 12, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29621780/short-term-results-of-intravitreal-triamcinolone-acetonide-combined-with-cataract-surgery-for-diabetic-macular-edema-in-japan-in-the-era-of-anti-vascular-endothelial-growth-factor-therapy
#4
Takayasu Nunome, Masahiko Sugimoto, Mineo Kondo, Chikako Suto
PURPOSE: To evaluate the effectiveness of an intravitreal triamcinolone acetonide injection (IVTA) combined with cataract surgery for diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (anti-VEGF) therapy. PROCEDURE: IVTA combined with cataract surgery was performed on 29 eyes of patients with DME (aged 70.5 ± 6.2 years) who were refractive to anti-VEGF treatments. The visual acuity, central retinal thickness (CRT), and the central retinal sensitivity were assessed at 1, 4, 12, and 24 weeks after the treatment...
April 5, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29576875/current-advances-in-pharmacotherapy-and-technology-for-diabetic-retinopathy-a-systematic-review
#5
REVIEW
Lei Lu, Ying Jiang, Ravindran Jaganathan, Yanli Hao
Diabetic retinopathy (DR) is classically defined by its vascular lesions and damage in the neurons of the retina. The cellular and clinical elements of DR have many features of chronic inflammation. Understanding the individual cell-specific inflammatory changes in the retina may lead to novel therapeutic approaches to prevent vision loss. The systematic use of available pharmacotherapy has been reported as a useful adjunct tool to laser photocoagulation, a gold standard therapy for DR. Direct injections or intravitreal anti-inflammatory and antiangiogenesis agents are widely used pharmacotherapy to effectively treat DR and diabetic macular edema (DME)...
2018: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29380765/analysis-of-yield-of-retinal-imaging-in-a-rural-diabetes-eye-care-model
#6
Padmaja Kumari Rani, Yashaswee Bhattarai, Sethu Sheeladevi, K ShivaVaishnavi, Md Hasnat Ali, J Ganesh Babu
PURPOSE: The aim of this study is to analyze the yield of retinal images obtained in a rural diabetes eye care model. METHODS: An analysis of a sample of nonmydriatic fundus photography (NMFP) of posterior segment ophthalmic images, obtained by an indigenous equipment (3 nethra-Forus Royal), was done in a district-wide rural diabetic retinopathy (DR) screening program; a trained optometrist did the initial image grading. DR and diabetic macular edema (DME) were classified based on international DR and DME severity scale...
February 2018: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29062594/new-drugs-and-new-posterior-delivery-methods-in-cme
#7
João Rafael de Oliveira Dias, Renata Portella Nunes, Raquel Goldhardt
PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). RECENT FINDINGS: Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion related-CME and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME...
June 2017: Current Ophthalmology Reports
https://www.readbyqxmd.com/read/28764565/fluocinolone-acetonide-for-the-treatment-of-diabetic-macular-edema
#8
REVIEW
Daniele Veritti, Valentina Sarao, Laura Diplotti, Francesco Samassa, Paolo Lanzetta
Fluocinolone acetonide intravitreal implant is a non-erodible implant approved for the treatment of diabetic macular edema (DME) insufficiently responsive to available therapies. Areas covered: The injectable intravitreal implant releases fluocinolone acetonide at an average rate of 0.2 µg/day for at least 36 months. The two pooled pivotal FAME trials showed that, in patients with DME previously treated with laser photocoagulation, fluocinolone acetonide intravitreal implant was more beneficial than sham injection when looking at the proportion of patients with an improvement from baseline in visual acuity of more than 15 letters at 24 months and at 36 months...
October 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28427069/practical-lessons-from-protocol-i-for-the-management-of-diabetic-macular-edema
#9
REVIEW
Lekha Mukkamala, Neelakshi Bhagat, Marco A Zarbin
Protocol I, a multicenter randomized clinical trial, compared the visual outcomes of patients treated with 0.5 mg intravitreal ranibizumab with either prompt or deferred (by 24 weeks laser), 4 mg intravitreal triamcinolone with prompt laser, or sham injection with prompt laser for the treatment of center-involving diabetic macular edema (DME). A total of 854 adult patients with type I or II diabetes and any level of non-proliferative diabetic retinopathy or proliferative retinopathy with adequate panretinal photocoagulation, with best-corrected visual acuity (BCVA) of 78 to 24 ETDRS letters (Snellen equivalent of 20/32 to 20/320) and visual loss attributed to macular edema, or retinal thickening with central subfield thickness of at least 250 µm by OCT were enrolled...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427068/intravitreal-steroids-in-diabetic-macular-edema
#10
REVIEW
Rosangela Lattanzio, Maria Vittoria Cicinelli, Francesco Bandello
Over the past decade, great strides have been made in the management of diabetic macular edema (DME). Therapeutic alternatives now include focal/grid laser photocoagulation, vitreo-retinal surgery, and intraocular injection of anti-angiogenic and steroid molecules. Intravitreal administration of steroids represents a fundamental alternative for recalcitrant and naive eyes with DME, especially in those cases when anti-vascular endothelial growth factor (VEGF) agents are contraindicated or a treatment regimen with fewer intravitreal injections is required...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28283896/fluocinolone-acetonide-intravitreal-implant-0-19%C3%A2-mg-iluvien-%C3%A2-a-review-in-diabetic-macular-edema
#11
REVIEW
Yahiya Y Syed
Fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN(®)) is a nonbiodegradable, injectable, corticosteroid implant that is approved in several countries, including the USA, for the treatment of diabetic macular edema (DME). ILUVIEN(®) releases fluocinolone acetonide at an initial rate of 0.25 µg/day (average rate 0.2 µg/day) and lasts 36 months. In the two pooled pivotal FAME trials in patients with DME previously treated with macular laser photocoagulation, fluocinolone acetonide intravitreal implant 0...
April 2017: Drugs
https://www.readbyqxmd.com/read/28165610/diabetic-macular-edema-outcomes-in-eyes-treated-with-fluocinolone-acetonide-0-2-%C3%A2%C2%B5g-d-intravitreal-implant-real-world-uk-experience
#12
MULTICENTER STUDY
Ibraheem El-Ghrably, David H W Steel, Maged Habib, Daniela Vaideanu-Collins, Sridhar Manvikar, Roxane J Hillier
PURPOSE: To conduct an observational, multicenter study to evaluate real-world clinical efficacy and safety of the 0.2 µg/day fluocinolone acetonide (FAc) implant in the treatment of patients with chronic diabetic macular edema (DME) in 3 large hospital ophthalmology departments in the United Kingdom. METHODS: Fluocinolone acetonide implants were inserted into the study eyes following a suitable washout period; phakic eyes received FAc implant following cataract surgery...
May 11, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28009415/dexamethasone-intravitreal-implant-at-the-time-of-cataract-surgery-in-eyes-with-diabetic-macular-edema
#13
Giacomo A Panozzo, Elena Gusson, Giorgio Panozzo, Giulia Dalla Mura
PURPOSE: To determine the potential role of intraoperative dexamethasone intravitreal implant (DEX-I) in reducing diabetic macular edema (DME) worsening after phacoemulsification. METHODS: This was a prospective study on 19 eyes of 19 patients with type 2 diabetes mellitus with DME and cataract. Mean preoperative Early Treatment Diabetic Retinopathy Study visual acuity (VA) was 16.7 letters. Mean foveal thickness (FT) was 451 μm. The DME was naive in 11 eyes and refractory in 8 eyes...
June 26, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/27993483/lens-power-axial-length-to-corneal-radius-ratio-and-association-with-diabetic-retinopathy-in-the-adult-population-with%C3%A2-type-2-diabetes
#14
Jiangnan He, Xian Xu, Jianfeng Zhu, Bijun Zhu, Bo Zhang, Lina Lu, Xiangui He, Xuelin Bai, Xun Xu, Haidong Zou
PURPOSE: To calculate crystalline lens power and to determine the relationship between ocular biometry and diabetic retinopathy (DR) in an adult population with type 2 diabetes mellitus (T2DM). DESIGN: Cross-sectional, population-based study. PARTICIPANTS: Patients with T2DM from the Beixinjing community, Changning district, Shanghai. METHODS: Random clustering sampling was used to identify adults with T2DM in the Beixinjing community...
March 2017: Ophthalmology
https://www.readbyqxmd.com/read/27926909/dexamethasone-implant-in-chronic-diabetic-macular-edema-resistant-to-intravitreal-ranibizumab-treatment
#15
Ozlem Eski Yucel, Ertugrul Can, Hilal Eser Ozturk, Hakki Birinci, Yuksel Sullu
PURPOSE: The aim of this study was to assess the efficacy of a single intravitreal dexamethasone implant (IDI) over 6 months in eyes with chronic diabetic macular edema (DME) that were resistant to intravitreal ranibizumab (IR) treatment. METHODS: This retrospective study was conducted at the Ondokuz Mayis University Hospital, Samsun, Turkey. Efficacy outcomes were considered as the change from baseline in best corrected visual acuity (BCVA) and central macular thickness (CMT)...
2017: Ophthalmic Research
https://www.readbyqxmd.com/read/27754737/comparative-effects-of-topical-diclofenac-and-betamethasone-on-inflammation-after-vitrectomy-and-cataract-surgery-in-various-vitreoretinal-diseases
#16
COMPARATIVE STUDY
Kanako Yasuda, Ryosuke Motohashi, Osamu Kotake, Hayate Nakagawa, Hidetaka Noma, Masahiko Shimura
PURPOSE: To compare the effects of topical diclofenac and betamethasone on postoperative inflammation after combined sutureless cataract and vitreoretinal surgery in patients with macular hole (MH), epiretinal membrane (ERM), diabetic macular edema (DME), and rhegmatogenous retinal detachment (RRD). METHODS: The study involved 180 eligible eyes that underwent the combined surgery, followed by treatment with topical diclofenac (n = 100) or betamethasone (n = 80) for 12 weeks...
December 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27661663/management-of-macular-oedema-in-diabetic-patients-undergoing-cataract-surgery
#17
REVIEW
Francesco Boscia, Ermete Giancipoli, Giuseppe D'Amico Ricci, Antonio Pinna
PURPOSE OF REVIEW: The aim of this study was to describe all the treatment modalities used to prevent and manage macular oedema in diabetic patients undergoing cataract surgery. RECENT FINDINGS: Topical NSAIDs have been proposed to be an effective strategy to prevent postsurgical macular oedema (PME) in diabetic patients. The prophylactic use of intravitreal antivascular endothelial growth factors (anti-VEGF) drugs and steroids in these patients, even if effective, brings some concerns with regard to possible side effects...
January 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27660409/update-on-corticosteroids-for-diabetic-macular-edema
#18
REVIEW
Stephen G Schwartz, Ingrid U Scott, Michael W Stewart, Harry W Flynn
Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27651226/intravitreal-aflibercept-for-diabetic-macular-edema-148-week-results-from-the-vista-and-vivid-studies
#19
RANDOMIZED CONTROLLED TRIAL
Jeffrey S Heier, Jean-François Korobelnik, David M Brown, Ursula Schmidt-Erfurth, Diana V Do, Edoardo Midena, David S Boyer, Hiroko Terasaki, Peter K Kaiser, Dennis M Marcus, Quan D Nguyen, Glenn J Jaffe, Jason S Slakter, Christian Simader, Yuhwen Soo, Thomas Schmelter, Robert Vitti, Alyson J Berliner, Oliver Zeitz, Carola Metzig, Frank G Holz
PURPOSE: To compare efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME) over 3 years. DESIGN: Two similarly designed phase 3 trials: VISTADME and VIVIDDME . PARTICIPANTS: Patients (eyes; n = 872) with central-involved DME. METHODS: Eyes received IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser control...
November 2016: Ophthalmology
https://www.readbyqxmd.com/read/27632215/a-multicenter-12-month-randomized-study-comparing-dexamethasone-intravitreal-implant-with-ranibizumab-in-patients-with-diabetic-macular-edema
#20
RANDOMIZED CONTROLLED TRIAL
David G Callanan, Anat Loewenstein, Sunil S Patel, Pascale Massin, Borja Corcóstegui, Xiao-Yan Li, Jenny Jiao, Yehia Hashad, Scott M Whitcup
PURPOSE: To evaluate whether treatment with dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months provides a similar average change in best-corrected visual acuity (BCVA) from baseline as ranibizumab 0.5 mg administered as per its European Summary of Product Characteristics in patients with diabetic macular edema (DME). METHODS: This was a multicenter, open-label, 12-month, randomized, parallel-group, noninferiority study in patients with DME (one eye/patient)...
March 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
keyword
keyword
61796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"